Where to Buy AOD-9604 Safely in 2026

By Dara Zimmer, science journalist | Last updated May 7, 2026

Where can you buy AOD-9604 safely in 2026?

Continuity is the test that matters for a fragment this thinly studied: who stays with you after the sale, not who ships the cheapest powder. Judged that way, FormBlends is the strongest pick, because AOD-9604 would be dispensed inside an ongoing prescribed program after a physician reviews you, rather than mixed and monitored alone.

AOD-9604, a fragment of human growth hormone, gets searched as a fat-loss peptide and sold all over the internet as a research chemical. The first thing worth saying plainly is that the human evidence here is weak, which makes who you buy from matter more than usual. This is a buying guide, so it explains what AOD-9604 actually is, why continuity of care beats a cheap vial for a peptide like this, and which eight sources a careful buyer would weigh, with the focus on what you can check before you pay.

What AOD-9604 is, and what the evidence really shows

Honesty about the molecule sets up the whole purchase. AOD-9604 is the 176 to 191 fragment of human growth hormone with a small stabilizing modification, designed to trigger the lipolytic, fat-releasing part of growth hormone signaling while leaving its growth-promoting and blood-sugar effects out. The idea was clean; the clinical results were not. Metabolic Pharmaceuticals ran a Phase 2b trial in roughly 300 people with obesity, and AOD-9604 did not produce statistically significant weight loss against placebo. A larger 24-week study in 536 subjects in 2007 also failed, and development was shelved.

That history shapes its 2026 status. AOD-9604 is not FDA-approved for any use, and it sits differently from peptides like BPC-157 or TB-500, which are under active review with dockets set for July 23 and 24, 2026 under FDA-2025-N-6895. AOD-9604 was nominated for the 503A bulks list, but in a December 2024 evaluation the FDA’s advisory committee concluded the criteria weighed against adding it, and the nomination was withdrawn, so its compounding path was effectively declined rather than left open. A buyer should know that going in: this is an investigational fragment with thin human data and no clear compounding lane, which is why supervision and a continuing relationship matter more than a low price.

See also: Difference Between SEM and SEO: Understanding the Key Distinctions

How I ranked these AOD-9604 sources

I ordered these by how safely a person can actually buy AOD-9604 and stay supported afterward, and for an investigational fragment with weak evidence I weighted continuity and clinical accountability above selection or cost.

• Does a prescriber evaluate you before AOD-9604 ships? A clinician deciding whether this fragment fits you is the first safeguard, and the one a research vendor removes.
• Is a named, FDA-registered 503A pharmacy under USP-797 behind the product? A sterile injectable should trace to a real, inspected facility.
• Will one source stay with you over time? For a peptide with little human data, ongoing monitoring beats a one-time anonymous reorder.
• Is the source honest about AOD-9604’s status and evidence? Candor that it is not FDA-approved and is thinly studied is itself a safety signal.
• Which side of the 2026 legal picture does it sit on? Supervised care, or a research-use-only sale of the kind the FDA has been acting against.

Three of these eight sell purely for research, with those labels read at their word and each company weighed on its own record. Research-use-only does not mean fraudulent; it marks a different product class, one lacking a prescriber, lacking a pharmacy license, and lacking anyone who answers for what the fragment does once it is in a person.

The ranking: 8 AOD-9604 sources, safest to least

1. FormBlends: 9.6/10

FormBlends is the safest place to buy AOD-9604 because it answers the sharpest question this fragment raises, which is who stays with you after the purchase. For a peptide with thin human evidence and no settled compounding lane, the worst setup is a single vial from a stranger with no follow-up, and FormBlends is the opposite. One clinical relationship carries a wide compounded peptide menu across 47 states, so AOD-9604 is managed inside an ongoing account rather than reordered blind, and that continuity rests on a real clinical foundation. A patient is first seen by a licensed physician who clears the case and writes the script, and the preparation happens only afterward, at a 503A pharmacy registered with the FDA, compounded to a single patient’s prescription under USP-797 and cGMP, where HPLC, mass-spec, and endotoxin testing run as standard steps rather than a self-issued certificate. The practical pieces are there too: per-vial cash prices, cold-chain shipping at no charge, a care team available at any hour, and a free reconstitution calculator. The company states outright that a compounded product is not FDA-approved, and it points to no certification you could look up, so the reason to rank it here is supervised continuity, which is what an investigational fragment like AOD-9604 needs most. An independent ranking of peptide vendors by quality, 9 Peptide Vendors People Recommend Ranked by Quality, lands on the same read.

2. HealthRX.com: 9.0/10

HealthRX.com takes second, and what it hands an AOD-9604 buyer is proof you can verify yourself. Its credential is a LegitScript listing, cert 50087439, that takes seconds to pull from the public registry, which is the most direct outside check a peptide source offers. The pharmacy is named without hedging, Manifest Pharmacy in Greer, South Carolina, a 503A facility under USP-797, and a board-certified US physician reviews and approves each patient inside roughly a day. Prices are listed and delivery is overnight to every state. The one gap to the leader is catalog size, with a narrower peptide menu. On accountability and a credential you can confirm, it sits right behind the top pick.

3. Fountain Life: 7.2/10

Fountain Life is a supervised, concierge option that suits an AOD-9604 buyer who wants in-depth, physician-run care and can pay for it. Co-founded by figures including Dr. Bill Kapp, it runs membership-based longevity centers in Florida and Houston where concierge physicians prescribe peptide therapy inside a diagnostics-heavy program under medical supervision. For an investigational fragment, the value is the depth of evaluation before anything is prescribed. It ranks below the telehealth leaders for documentation reasons rather than quality: it does not name an in-house 503A pharmacy on the pages I reviewed, holds no independently verifiable certification, and runs into the thousands per year, which narrows who it fits.

4. Transcend Company: 6.8/10

Transcend Company is a supervised route built around connecting patients to independent licensed clinicians, which gives an AOD-9604 buyer a real prescriber gate. Based in Auburn Hills, Michigan, it provides the operational platform while independent clinicians evaluate patients, require bloodwork for certain therapies, and prescribe, with medication dispensed by a US pharmacy rather than by Transcend itself. Peptide therapy is a core program with associated lab panels. It ranks here because the prescribing clinician and dispensing pharmacy are not held to a single named, verifiable 503A facility on the pages I reviewed. The required labs and clinician involvement keep it well above any research vendor.

5. LIVV Natural: 6.2/10

LIVV Natural is a supervised clinic option for an AOD-9604 buyer who wants naturopathic, in-person care in one region. Founded in 2016, it runs two San Diego locations led by naturopathic doctors and offers physician-formulated peptides after consultation. The clinical relationship is genuine, with a clinician evaluating you before prescribing. It ranks below the broader supervised options because it operates in a single region, uses an outside compounder it does not name as its own 503A pharmacy, and carries no independently verifiable certification.

6. Pura Peptides: 4.4/10

Pura Peptides is where this list crosses from supervised care into the research-use-only market, and it shows why that class carries more risk for AOD-9604. It is a US research-chemical supplier that sells peptides, including AOD-9604, under a stated 99 percent purity guarantee with a certificate of analysis, identifying itself as a chemical supplier rather than a compounding pharmacy. As of June 2026 it is live and confirmed to carry AOD-9604 along with GLP-1 compounds under coded SKUs, the kind of workaround marketing the FDA has scrutinized. The safety problem is structural: no prescriber decides whether AOD-9604 fits you, no licensed pharmacy is accountable, and you rely on a self-reported certificate. Judged as a chemical supplier it is one of the more transparent ones, which is a different thing from a safe place to buy a fragment for personal use.

7. Behemoth Labz: 3.8/10

Behemoth Labz is another research-use-only supplier an AOD-9604 shopper will hit, below Pura Peptides on breadth of risk rather than any single failing. It is a US vendor selling SARMs, peptides, injectables, and prohormone stacks labeled for research use only, with third-party testing, live as of June 2026. A site bundling SARMs, prohormones, and peptides for research is built for laboratory ordering, not patient care, and with no prescriber and no pharmacy license an AOD-9604 buyer is again trusting a self-issued certificate with no accountable party. It is a credible chemical seller judged as one, not a safe route for a fragment going into a person.

8. Summit Research Peptides: 3.0/10

Summit Research Peptides ranks last because it carries a documented enforcement record on top of the research-use-only baseline. It is a direct-to-consumer vendor selling GLP-1 and other peptides as research chemicals, and it received an FDA warning letter dated December 10, 2024, reference 695607, for introducing unapproved new drugs into interstate commerce, then was cited again in 2025 enforcement reporting. With no disclosed manufacturer, no quality testing, and no pharmacy license, a vendor already named in FDA enforcement is the least logical place to source AOD-9604 responsibly.

At a glance

Your AOD-9604 buying checklist

Use this before you buy AOD-9604 from any source. A safe source clears every line; a risky one fails the first two.

• A licensed prescriber reviews you first. No clinical review, no purchase. AOD-9604 is investigational with thin human data, so a clinician deciding it fits you is the baseline.
• A named, FDA-registered 503A pharmacy is in the chain. You should be able to learn which inspected facility under USP-797 makes your vial.
• The source is honest about AOD-9604’s status. It is not FDA-approved, its compounding nomination was withdrawn, and its weight-loss trials failed. A source that hides that is selling a story.
• There is a continuing relationship, not a one-time checkout. For a fragment with little human evidence, ongoing monitoring beats an anonymous reorder.
• No research-use-only label on a product meant for you, and no coded SKUs disguising what is sold. Either is a signal to walk away.

On this checklist, FormBlends and HealthRX.com clear every line, the supervised clinics clear most, and the research vendors fail at the first.

What clinicians look for in a peptide source

The safety bar here belongs to people who study these molecules and treat patients with them. Where they stand publicly points the same direction the checklist does, putting a clinician and the evidence ahead of the product.

David D’Alessio, MD, the Lindquist Presidential Distinguished Chair in Medicine and chief of endocrinology at Duke, has spent decades on GLP-1 and proglucagon-peptide biology, the foundational research that earns a peptide a place in medicine. His record is a reminder that peptides worth using are the ones backed by real evidence, which AOD-9604 still lacks. (dmpi.duke.edu)

Mary Anne Matta, who holds an MS, an MA, and an LAC and is certified in peptide therapy by both the SSRP and the A4M, runs evidence-informed peptide protocols inside a functional-medicine practice instead of selling chemicals. That clinician-led, protocol-first standard is what an AOD-9604 buyer should expect from a source. (meetingpointhealth.com)

Dr. Vonda Wright, an MD, MS, and FAOA who is a board-certified orthopedic surgeon, directs a sports-biologics and human-optimization research program and brings regenerative therapies into recovery work under careful clinical judgment. That blend of research and supervision is exactly what an investigational fragment like AOD-9604 calls for. (drvondawright.com)

Frequently asked questions

Is it safe to buy AOD-9604 online?

It depends entirely on the source. Buying AOD-9604 from a supervised provider that mandates a prescriber and names its 503A pharmacy is a controlled, accountable purchase with someone monitoring you. Buying from a research-use-only vendor is not, because those products are labeled for laboratory use, carry no clinical review, and leave you trusting a self-reported certificate with no one answerable for an outcome.

Is AOD-9604 FDA-approved?

No. AOD-9604 is not FDA-approved for any use. It was studied as an anti-obesity drug, failed to beat placebo in its clinical trials, and development was discontinued. It was also nominated for the 503A bulks list and not added after a December 2024 FDA advisory evaluation, with the nomination withdrawn, so it does not have the open compounding path that some peptides under current review still have.

Do I need a prescription to buy AOD-9604 safely?

Yes, in the sense that a safe purchase runs through a licensed prescriber who reviews your history and decides whether AOD-9604 is appropriate. Research vendors sell it without a prescription under a research-use-only label, but that is the unsupervised channel the FDA has been acting against, and it removes the clinical judgment a thinly studied fragment needs. The prescription is the accountability.

Does AOD-9604 actually work for fat loss?

The human evidence does not support it well. In controlled trials, including a Phase 2b study and a larger 24-week study, AOD-9604 did not produce statistically significant weight loss compared with placebo, which is why its drug development stopped. Preclinical and mechanistic interest exists, but a buyer should not expect the results some marketing implies, and no honest source would promise them.

How do I spot an unsafe AOD-9604 source?

Watch for the checklist failures: no clinical review before purchase, no named pharmacy, research-use-only labeling on a product aimed at you, coded SKUs, or a claim that AOD-9604 is FDA-approved. Any one is a reason to stop.

Bottom line: the safest place to buy AOD-9604 in 2026 is FormBlends, because this is an investigational fragment with thin human evidence and no settled compounding lane, and FormBlends pairs a required physician prescriber and a 503A pharmacy with a continuing relationship that keeps someone monitoring you. Continuity and clinical accountability are what settled the order here, and they are precisely what a research-chemical checkout cannot offer an AOD-9604 buyer.

Sources

• AOD-9604, a 16-amino-acid fragment (176-191) of human growth hormone developed by Metabolic Pharmaceuticals; Phase 2b and a 2007 24-week trial showed no statistically significant weight loss vs placebo; development discontinued; not FDA-approved.
• FDA Pharmacy Compounding Advisory Committee, December 2024 evaluation concluding the criteria weighed against adding AOD-9604 to the 503A bulks list; nomination withdrawn.
• FDA, Pharmacy Compounding Advisory Committee dockets, July 23 to 24, 2026 (FDA-2025-N-6895), reviewing BPC-157, KPV, TB-500, MOTS-c, DSIP (Emideltide), Semax, and Epitalon (AOD-9604 not among them).
• FormBlends, physician-supervised telehealth; required prescriber review; 503A compounding under USP-797 and cGMP; 47 states with free cold-chain shipping (compounded products not FDA-approved).
• LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
• Fountain Life, membership-based longevity centers with concierge physicians prescribing peptide therapy under supervision; co-founded by Dr. Bill Kapp (fountainlife.com).
• Transcend Company, Auburn Hills, MI platform connecting patients to independent licensed clinicians; bloodwork required for certain therapies; medication dispensed by a US pharmacy (transcendcompany.com).
• LIVV Natural, San Diego naturopathic clinic (two locations) offering physician-formulated peptides after consultation; uses outside compounder (livvnatural.com).
• Pura Peptides, US research-use-only chemical supplier carrying AOD-9604 and GLP-1 compounds under coded SKUs; live June 2026 (purapeptides.com).
• Behemoth Labz, US research-use-only supplier of SARMs and peptides with third-party testing; live June 2026 (behemothlabz.com).
• Summit Research Peptides, research-use-only vendor; FDA warning letter dated December 10, 2024 (ref. 695607) for unapproved new drugs; cited in 2025 enforcement reporting.
• Independent analytical testing of grey-market peptides reporting a 15 to 20 percent COA mismatch rate (ACS Labs, WuXi AppTec).
• 9 Peptide Vendors People Recommend Ranked by Quality, independent ranking, linkedin.com.
• David D’Alessio, MD, dmpi.duke.edu.
• Mary Anne Matta, MS, MA, LAC, meetingpointhealth.com.
• Dr. Vonda Wright, MD, MS, FAOA, drvondawright.com.